A Multi-locus Genetic Risk Score for Abdominal Aortic Aneurysm

Similar documents
Improving cardiometabolic health in Major Mental Illness

EHRs and large scale comparative effectiveness research

EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA

NGS and complex genetics

Overview. Total Joint Replacement in the U.S. KP National Total Joint Registry EMR Tools and Outcome Assessment: A Model for Vascular Surgery?

Listen to your heart: Good Cardiovascular Health for Life

Logistic Regression (1/24/13)

Big Data for Population Health and Personalised Medicine through EMR Linkages

Predicting The Risk Of Rheumatoid Arthritis

C-Reactive Protein and Diabetes: proving a negative, for a change?

PRACTICE PROBLEMS FOR BIOSTATISTICS

Main Effect of Screening for Coronary Artery Disease Using CT

School of Nursing. Presented by Yvette Conley, PhD

Impact of Massachusetts Health Care Reform on Racial, Ethnic and Socioeconomic Disparities in Cardiovascular Care

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

GENETIC DATA ANALYSIS

Epigenetic variation and complex disease risk

Results of streamlined regional ambulance transport and subsequent treatment of acute abdominal aortic aneurysm

Heritability: Twin Studies. Twin studies are often used to assess genetic effects on variation in a trait

Electronic Medical Records and Genomics: Possibilities, Realities, Ethical Issues to Consider

The Cross-Sectional Study:

FACILITATOR/MENTOR GUIDE

Abdominal Aortic Aneurysm (AAA) General Information. Patient information Leaflet

Psoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis

NHS Diabetes Prevention Programme (NHS DPP) Non-diabetic hyperglycaemia. Produced by: National Cardiovascular Intelligence Network (NCVIN)

Potentials for EHR Phenotyping in SJS/TEN

Genetics of Rheumatoid Arthritis Markey Lecture Series

Underwriting Critical Illness Insurance: A model for coronary heart disease and stroke

Traditional View of Diabetes. Are children with type 1 diabetes obese: What can we do? 8/9/2012. Change in Traditional View of Diabetes

Prognostic impact of uric acid in patients with stable coronary artery disease

GENETICS AND HEALTH INSURANCE

General and Abdominal Adiposity and Risk of Death in Europe

Major US Genomic Medicine Programs: NHGRI s Electronic Medical Records and Genomics (emerge) Network

Online Supplement to Polygenic Influence on Educational Attainment. Genotyping was conducted with the Illumina HumanOmni1-Quad v1 platform using

Are differences in methylation in cord blood DNA associated with prenatal exposure to alcohol?

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.

Preventive Services for Pregnancy SERVICE WHAT IS COVERED INTERVALS OF COVERAGE Anemia Screening Screening Annual screening for pregnant women

Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D.

Genetics for preventative cardiology. Objectives HEART DISEASE COMES IN MANY FORMS!

Social inequalities in all cause and cause specific mortality in a country of the African region

Refugees with diabetes mellitus have higher prevalence of latent tuberculosis infection

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

GENETICS AND INSURANCE: QUANTIFYING THE IMPACT OF GENETIC INFORMATION

Hormones and cardiovascular disease, what the Danish Nurse Cohort learned us

Summary ID# Clinical Study Summary: Study F3Z-JE-PV06

How To Determine Pad

A Markov model for long-term cost-effectiveness modelling of screening for abdominal aortic aneurysms

Core Facility Genomics

Mortality Assessment Technology: A New Tool for Life Insurance Underwriting

METABOLIC SYNDROME IN A CORRECTIONS POPULATION TREATED WITH ANTIPSYCHOTICS

06 Validation of risk prediction model

The Prevalence and Determinants of Undiagnosed and Diagnosed Type 2 Diabetes in Middle-Aged Irish Adults

Validation and Replication

FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES

Low diabetes numeracy predicts worse glycemic control

Genomics and Health Data Standards: Lessons from the Past and Present for a Genome-enabled Future

Incorporating Research Into Sight (IRIS) Essentia Rural Health Institute Marshfield Clinic Penn State University

Summary and conclusions. Chapter 8. Summary and conclusions

The Functional but not Nonfunctional LILRA3 Contributes to Sex Bias in Susceptibility and Severity of ACPA-Positive Rheumatoid Arthritis

Technical Issues in Aggregating and Analyzing Data from Heterogeneous EHR Systems

Principles of Hypothesis Testing for Public Health

Prevalence of alcohol consumption among Rheumatoid Arthritis patients on Methotrexate and impact on liver function tests

PARTICIPANT INFORMATION

Exploratory data: COPD and blood eosinophils. David Price: am

Multivariate Logistic Regression

on behalf of the AUGMENT-HF Investigators

Appendix: Description of the DIETRON model


Driving molecular pharmacology research utilizing EHRs and enhanced analytics:

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.

HLA-Cw*0602 associates with a twofold higher prevalence. of positive streptococcal throat swab at the onset of

Diabetes Prevention in Latinos

CARDIOVASCULAR PROBLEMS IN SURVIVORS OF CHILDHOOD CANCER AND THEIR SIBLINGS

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

FACTORS ASSOCIATED WITH HEALTHCARE COSTS AMONG ELDERLY PATIENTS WITH DIABETIC NEUROPATHY

Factors for success in big data science

Combining Data from Different Genotyping Platforms. Gonçalo Abecasis Center for Statistical Genetics University of Michigan

Presentation by: Ahmad Alsahaf. Research collaborator at the Hydroinformatics lab - Politecnico di Milano MSc in Automation and Control Engineering

Atherosclerosis of the aorta. Artur Evangelista

GAW 15 Problem 3: Simulated Rheumatoid Arthritis Data Full Model and Simulation Parameters

Addressing Racial/Ethnic Disparities in Hypertensive Health Center Patients

Atrial Fibrillation: A Different Perspective. Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Renal cell carcinoma and body composition:

The Scottish Health Survey

Estimating the Completeness of Physician Billing Claims for Diabetes Case Ascertainment

Importance of Statistics in creating high dimensional data

Using EHRs for Heart Failure Therapy Recommendation Using Multidimensional Patient Similarity Analytics

Use of the Chi-Square Statistic. Marie Diener-West, PhD Johns Hopkins University

Building risk prediction models - with a focus on Genome-Wide Association Studies. Charles Kooperberg

R.P. Zecchin*, J. Baihn, Y.Y. Chai, J. Hungerford, G. Lindsay, M. Owen, J. Thelander, D.L. Ross, C. Chow, A.R. Denniss. Westmead Hospital, Sydney,

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone

Conveners: S. Bruno, C.M. Mastroianni

Cohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University

Investigating the genetic basis for intelligence

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES

Research Article Cardiovascular Risk in Psoriasis: A Population-Based Analysis with Assessment of the Framingham Risk Score

The M.U.R.D.O.C.K. Study

The birth of the population-based cohort studies in preventive medicine From Framingham to Värmland

Transcription:

A Multi-locus Genetic Risk Score for Abdominal Aortic Aneurysm Zi Ye, 1 MD, Erin Austin, 1,2 PhD, Daniel J Schaid, 2 PhD, Iftikhar J. Kullo, 1 MD Affiliations: 1 Division of Cardiovascular Diseases and the Gonda Vascular Center, Mayo Clinic, Rochester, MN; 2 Division of Health Science Research AHA ATVB 2015 2014 MFMER slide-1

Disclosure None 2014 MFMER slide-2

Background Abdominal aortic aneurysm (AAA): transverse diameter 3.0cm Prevalence: 12.8% in men; 4.1% in women above 65 years old respectively. Prognosis: mortality of 80% associated with aneurysm rupture; rupture determined by size and aneurysm growth rate Treatment: no pharmacological treatment is available to limit disease progression. 2014 MFMER slide-3

Background AAA is a multifactorial disease with a heritable component GWAS reported several common single nucleotide polymorphisms to be associated with AAA 2014 MFMER slide-4

Questions remain Identify biomarkers of AAA to improve disease prediction and enable individualized screening? Genetic risk improve prediction of presence of AAA beyond conventional risk factors? Genetic risk predict aneurysm growth? 2014 MFMER slide-5

Hypothesis A multi-locus genetic risk score (GRS) based on SNPs of GWAS may improve disease prediction beyond conventional risk factors and associated with aneurysm growth 2014 MFMER slide-6

Study design Case control study Study population: participants from Vascular Disease Biorepository. patients referred for noninvasive vascular evaluation in the Mayo Gonda Vascular Center and stress EKG lab, from 2008 to 2013, consent to give blood sample Ascertainment of conventional risk factors and comorbidities: electronic phenotype algorithms Information from institutional EHR Study questionnaire for smoking status 2014 MFMER slide-7

Study design Ascertainment of cases and non-cases: AAA: infrarenal abdominal aortic diameter 3 cm or history of aneurysm repair; Non-AAA: without ICD-9 codes of aortic aneurysm Aneurysm growth rate: latest/pre-operation first diameter / time interval (mm/ year) 2014 MFMER slide-8

Study design-genotyping Genomic DNA extracted from whole blood samples drawn at the recruitment Performed in Mayo clinic core lab using Illumina infinium Human core Exome Array, Ilumina Human 610 and 660w Quad-v1 (call rates>95%) Candidate SNPs from GWAS catalog and Pubmed. 2014 MFMER slide-9

Study design-grs Z-test to assess whether the risk estimates of SNPs were substantially different from that in the published literature Candidate SNPs from independent loci (linkage disequilibrium=0) GRS calculation Genotype-informed estimation of risk of coronary heart disease based on genome-wide association data linked to the electronic medical record Keyue Ding, Kent R Bailey and Iftikhar J Kullo BMC Cardiovascular disease 2011, 11:66 2014 MFMER slide-10

Statistical methods Logistic regression analysis: presence of AAA as dependent variable Adjustment: 1) age and sex; and 2) additionally for BMI, hypertension, diabetes, dyslipidemia, ASCVD and family history of aortic aneurysm AUC and net reclassification index were estimated to assess whether GRS can improve disease prediction beyond conventional risk factors. Aneurysm growth rate 2014 MFMER slide-11

Results 2014 MFMER slide-12

Table. Associations of SNPs with presence of AAA Locus Gene SNPs (risk allele) MAF OR (95% CI) 19p13.2 LDLR rs6511720 (G) 0.90 1.32 (1.20-1.43) 12q13.3 LRP1 rs1466535(c) 0.58 1.15 (1.10-1.21) 9p33.2 DAB2IP rs7025846 (A) 0.23 1.21 (1.14-1.28) 9p21 CDKN2 A-2B In literature In VDB Z test P- MAF value 2x10^ -10 0.90 5x10^ -10 0.65 5x10^ -10 0.27 rs2383207 (T) 0.49 1.27 2x10^ -8 0.52 1p13.3 SORT1 rs599839 (G) 0.22 0.81 (0.76-0.85) 7.2x1 0^-14 0.23 OR (95% CI) 1.04 (0.89-1.21) 1.04 (0.94-1.15) 1.17 (1.05-1.29) 1.22 (1.11-1.34) 0.90 (0.80-1.00) P-value P- value 0.009 0.66 0.4 0.004 0.0001 0.06 0.08 0.54 0.51 0.14 2014 MFMER slide-13

Table. Patient characteristics AAA (n=1098) Non-AAA (n=6538) Age, years 74 (8) 67 (11) Men 915 (83) 4039 (62) Body mass index, kg/m 2 29.3 (4.9) 29.1 (5.6) *Smoking (ever) 952 (87) 3800 (58) *Hypertension 908 (82) 4203 (64) Type 2 diabetes 342 (25) 1819 (22) *Dyslipidemia 959 (87) 4931 (75) *ASCVD 966 (88) 4552 (70) *Family history of aortic aneurysm 178 (16) 471 (7) *GRS 5.34 (2.74) 4.89 (2.86) Values expressed as mean (SD) or number (%).*P-value < 0.05 for comparisons in cases vs. non-cases adjusted for age and sex. Abbreviations: AAA=abdominal aortic aneurysm; ASCVD=atherosclerotic cardiovascular disease; GRS=genetic risk score. 2014 MFMER slide-14

Age & sex adjusted odds ratio for AAA Covariates OR ( 95% CI) GRS above median 1.37 (1.20-1.56) FHx of AA 2.49 (2.04-3.02) ASCVD 2.74 (2.26-3.34) Type 2 diabetes 1.00 (0.86-1.17) Dyslipidemia 2.02 (1.67-2.45) Hypertension 2.43 (2.06-2.89) Smoker 3.55 (2.96-4.28) BMI 30kg/m2 1.02 (0.89-1.17) 0 1 2 3 4 5 2014 MFMER slide-15

Multivariable regression analysis: odds ratio for presence of AAA Covariates OR ( 95% CI) Age >65 years 1.55 (1.35-1.77) Male sex 2.98 (2.52-3.56) GRS above median 1.31 (1.14-1.50) FHx of AA 2.43 (1.96-2.98) ASCVD 2.09 (1.70-2.59) Type 2 diabetes 0.78 (0.66-0.92) Dyslipidemia 1.32 (1.07-1.65) Hypertension 1.86 (1.54-2.26) Smoker 3.35 (2.77-4.06) BMI 30kg/m2 0.93 (0.80-1.07) 0 1 2 3 4 5 2014 MFMER slide-16

Association with AAA size change (N=628) 45% 55% Growth rate median 55% 45% Growth rate < median GRS < median GRS median GRS < median GRS median Linear regression Beta (SE) P-value AAA size baseline 1.29 (0.13) <0.001 GRS median 0.44 (0.20) 0.03 Logistic regression OR (95% CI) P- value AAA size baseline 2.78 (2.18-3.57) <0.001 GRS median 1.5 (1.07-2.11) 0.02 2014 MFMER slide-17

Conclusions A multi-locus GRS was associated with presence of AAA and greater aneurysm growth, suggesting genetic predisposition to disease initiation and progression 2014 MFMER slide-18

Limitations May not generalized to other population Not non-diseased participants with ultrasound screening GRS built based on additive model that may be an over simplification of the true biological mechanism 2014 MFMER slide-19

Questions & Discussion 2014 MFMER slide-20